MetaCap

Quoin Pharmaceuticals (QNRX) vs Quantum Biopharma (QNTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

Quoin Pharmaceuticals (QNRX) has outperformed Quantum Biopharma (QNTM) over the past year, losing 44.4% versus a loss of 80.3%. Over five years, QNTM leads with a -96.7% price change compared with -100.0% for QNRX. Quoin Pharmaceuticals is the larger company by market cap ($21.6 million vs $18.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

QNRX-44.44%QNTM-80.28%
+185%+43%-100%
Oct 8, 20251 yearOct 8, 2026
QNRX-100.00%QNTM-96.72%
+34%-36%-106%
Oct 4, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

QNRX versus QNTM key metrics
MetricQNRXQNTM
Share price$4.50$2.94
Market cap$21.62M$18.90M
1-day change-1.10%-5.47%
YTD return-68.47%-57.40%
1-year return-44.44%-80.28%
5-year return-99.99%-96.65%
EPS (TTM)$-5.67$-4.98
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$41.80$16.36
52-week low$3.25$2.07
Distance from 52-week high-89.23%-82.03%
Analyst consensusnonenone
Avg. price target upside+385.11%+317.35%
Average volume541.11K205.30K
Shares outstanding4.80M6.43M
Employees4—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • QNRX has outperformed QNTM by 35.8 percentage points over the past year.

About Quoin Pharmaceuticals

QNRX stock →

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Quantum Biopharma

QNTM stock →

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.

Health Care · Biotechnology: Pharmaceutical Preparations

QNRX vs QNTM FAQ

Which is bigger, Quoin Pharmaceuticals or Quantum Biopharma?

Quoin Pharmaceuticals (QNRX) is larger, with a market capitalization of $21.62M compared with $18.90M for Quantum Biopharma (QNTM).

Which stock has performed better over the past year, QNRX or QNTM?

QNRX returned -44.44% over the past 12 months, compared with -80.28% for QNTM (price return, excluding dividends). Past performance does not predict future results.

Are Quoin Pharmaceuticals and Quantum Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons